Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12264385 | 0.85 | PPARA (0.47) | PPARAPTGS2P2RX7LMNAALDH1A1 | |
| SCHEMBL2857382 | 0.82 | LMNA (0.53) | MEN1KMT2APTGS2LMNAPOLB | |
| SCHEMBL9441588 | 0.79 | CYP2C9 (0.56) | PPARAMEN1KMT2AP2RX7ALDH1A1 | |
| SCHEMBL14482912 | 0.77 | MEN1 (0.47) | PPARAMEN1KMT2APTGS2LMNA | |
| SCHEMBL14482943 | 0.77 | LMNA (0.49) | MEN1KMT2APTGS2LMNAALDH1A1 | |
| SCHEMBL14482198 | 0.76 | MEN1 (0.81) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2564655 | 0.76 | PPARA (0.46) | PPARAMEN1KMT2APTGS2P2RX7 | |
| SCHEMBL23147100 | 0.71 | LMNA (0.51) | PPARAMEN1KMT2APTGS2LMNA | |
| SCHEMBL20551576 | 0.71 | HPGD (0.56) | MEN1KMT2APTGS2LMNAPOLB | |
| SCHEMBL4422536 | 0.71 | ALDH1A1 (0.75) | PPARAMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716485-B2 | Pyrazole synthesis by coupling of carboxylic acid derivatives and enamines | WESTFÄLISHE WILHELMS-UNIVERSITÄT MÜNSTER (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130012715-A1 | PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES | WESTFAELISCHE WILHELMS UNIVERSITAET MUENSTER (DE) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012715-A1 | PYRAZOLE SYNTHESIS BY COUPLING OF CARBOXYLIC ACID DERIVATIVES AND ENAMINES | PC, ENO1, PDK2 | PPARA 176/4885MEN1 2319/4885KMT2A 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.